Evolving Treatment Strategies in High-Risk Neuroblastoma - Episode 8

Anti-GD2 Monoclonal Antibodies in Patients With R/R HRNB: Pivotal Clinical Trials

September 28, 2023

Drs Sholler and Agrawal detail recent studies on naxitamab and dinutuximab demonstrating effectiveness in treating recurrent or refractory neuroblastoma, leading to their FDA approvals, and significantly influencing treatment practices.

EP. 1: An Overview of Neuroblastoma

EP. 2: Approaches to Diagnosing Neuroblastoma

EP. 3: Role of CURIE Scores in the Treatment and Management of Neuroblastoma

EP. 4: Current Treatment Paradigm for Newly Diagnosed Neuroblastoma

EP. 5: Differentiating Refractory and Relapsed Neuroblastoma

EP. 6: Updated Data From the LEAHRN Study in High-Risk Neuroblastoma

EP. 7: Available Treatment Options for Recurrent/Relapsed High-Risk Neuroblastoma (R/R HRNB)

Now Viewing

EP. 8: Anti-GD2 Monoclonal Antibodies in Patients With R/R HRNB: Pivotal Clinical Trials

EP. 9: Strategies for Adverse Effect Management and Treatment Optimization With Anti-GD2 Monoclonal Antibodies in R/R

EP. 10: Future Perspectives in the Treatment of Neuroblastoma